United Therapeutics price target lowered to $280 from $300 at Argus

Argus analyst Jasper Hellweg lowered the firm’s price target on United Therapeutics to $280 from $300 but keeps a Buy rating on the shares ahead of its Q1 results. The stock has underperformed over the past three months, but given the continued strong performance of Tyvaso, the study of Tyvaso for new indications, the promising organ manufacturing and transplant programs, and the company’s strong balance sheet and pipeline, the firm sees upside for shares over the next year, the analyst tells investors in a research note.